On 2 July 2014, the Swedish Medical Products Agency, which is the Swedish competent authority for the purposes of Regulation (EC) No 1223/2009, adopted and communicated a decision under Article 27 of Regulation (EC) No 1223/2009 introducing provisional restrictive measures on a nail cosmetic product that had caused a high number of undesirable effects. The substances identified as likely to cause those undesirable effects were HEMA and Di-HEMA TMHDC.
Recital 2, Regulation (EU) 2020/1682
In force